Drug Information

Drug General Information
Drug ID
D0S6PV
Former ID
DNC003903
Drug Name
VOLINANSERIN
Drug Type
Small molecular drug
Indication Discovery agent Phase 3 [522480], [539159]
Structure
Download

3D MOL
Formula
C22H28FNO3
InChI
InChI=1S/C22H28FNO3/c1-26-20-5-3-4-19(22(20)27-2)21(25)17-11-14-24(15-12-17)13-10-16-6-8-18(23)9-7-16/h3-9,17,21,25H,10-15H2,1-2H3/t21-/m1/s1
InChIKey
HXTGXYRHXAGCFP-OAQYLSRUSA-N
CAS Number
CAS 139290-65-6
PubChem Compound ID
5311271
PubChem Substance ID
7979872, 11056395, 12014670, 14755501, 14804188, 39340971, 80773858, 91616570, 103275460, 103992797, 114155712, 124954269, 128128333, 134341108, 135650573, 137231458, 143057684, 144210564, 162249020, 164766144, 170500892, 176224358, 185997000, 198966064, 208265419, 215780295, 223532818, 223782286, 226970760, 241034286, 249735007, 252157845, 252159862, 252322025, 252821118
Target and Pathway
Target(s) 5-hydroxytryptamine 2A receptor Target Info Inhibitor [530045]
Potassium voltage-gated channel subfamily H member 2 Target Info Inhibitor [530936]
5-hydroxytryptamine 2C receptor Target Info Inhibitor [530936]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Serotonergic synapse
Inflammatory mediator regulation of TRP channelshsa04020:Calcium signaling pathway
Inflammatory mediator regulation of TRP channels
PANTHER Pathway 5HT2 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathway
PathWhiz Pathway Muscle/Heart Contraction
Reactome Serotonin receptors
G alpha (q) signalling eventsR-HSA-1296072:Voltage gated Potassium channelsR-HSA-390666:Serotonin receptors
G alpha (q) signalling events
WikiPathways Serotonin Receptor 2 and STAT3 Signaling
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
SIDS Susceptibility Pathways
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signaling
GPCRs, OtherWP706:SIDS Susceptibility Pathways
Hematopoietic Stem Cell Differentiation
Potassium ChannelsWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
References
Ref 522480ClinicalTrials.gov (NCT00788515) Comparison of Volinanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties. U.S. National Institutes of Health.
Ref 539159(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 185).
Ref 530045Bioorg Med Chem. 2009 Apr 15;17(8):2989-3002. Epub 2009 Mar 14.Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.
Ref 530936Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12. Epub 2010 Apr 24.Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists for the treatment of sleep disorders.